202 related articles for article (PubMed ID: 37943402)
1. Research progress of good markers for canine mammary carcinoma.
Yang NY; Zheng HH; Yu C; Ye Y; Du CT; Xie GH
Mol Biol Rep; 2023 Dec; 50(12):10617-10625. PubMed ID: 37943402
[TBL] [Abstract][Full Text] [Related]
2. Current biomarkers of canine mammary tumors.
Kaszak I; Ruszczak A; Kanafa S; Kacprzak K; Król M; Jurka P
Acta Vet Scand; 2018 Oct; 60(1):66. PubMed ID: 30373614
[TBL] [Abstract][Full Text] [Related]
3. Expression of TopBP1 in canine mammary neoplasia in relation to histological type, Ki67, ERalpha and p53.
Morris JS; Nixon C; King OJ; Morgan IM; Philbey AW
Vet J; 2009 Mar; 179(3):422-9. PubMed ID: 18314357
[TBL] [Abstract][Full Text] [Related]
4. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors.
Lee CH; Kim WH; Lim JH; Kang MS; Kim DY; Kweon OK
J Vet Sci; 2004 Mar; 5(1):63-9. PubMed ID: 15028887
[TBL] [Abstract][Full Text] [Related]
5. The potential role of COX-2 in cancer stem cell-mediated canine mammary tumor initiation: an immunohistochemical study.
Huang J; Zhang D; Xie F; Lin D
J Vet Sci; 2015; 16(2):225-31. PubMed ID: 26124697
[TBL] [Abstract][Full Text] [Related]
6. Ki-67 and PCNA Expression in Canine Mammary Tumors and Adjacent Nonneoplastic Mammary Glands: Prognostic Impact by a Multivariate Survival Analysis.
Carvalho MI; Pires I; Prada J; Lobo L; Queiroga FL
Vet Pathol; 2016 Nov; 53(6):1138-1146. PubMed ID: 27162119
[TBL] [Abstract][Full Text] [Related]
7. Reduced canine BRCA2 expression levels in mammary gland tumors.
Yoshikawa Y; Morimatsu M; Ochiai K; Ishiguro-Oonuma T; Wada S; Orino K; Watanabe K
BMC Vet Res; 2015 Jul; 11():159. PubMed ID: 26202431
[TBL] [Abstract][Full Text] [Related]
8. Different role of COX-2 and angiogenesis in canine inflammatory and non-inflammatory mammary cancer.
Clemente M; Sánchez-Archidona AR; Sardón D; Díez L; Martín-Ruiz A; Caceres S; Sassi F; Dolores Pérez-Alenza M; Illera JC; Dunner S; Peña L
Vet J; 2013 Aug; 197(2):427-32. PubMed ID: 23489848
[TBL] [Abstract][Full Text] [Related]
9. PKM2 in Canine Mammary Tumors: Parallels to Human Breast Cancer.
Lee HJ; Han HJ; Lee JY; Son WC
Comp Med; 2020 Aug; 70(4):349-354. PubMed ID: 32718384
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical vascular factor expression in canine inflammatory mammary carcinoma.
Camacho L; Peña L; Gil AG; Martín-Ruiz A; Dunner S; Illera JC
Vet Pathol; 2014 Jul; 51(4):737-48. PubMed ID: 24048323
[TBL] [Abstract][Full Text] [Related]
11. Mutations of p53 tumor suppressor gene in spontaneous canine mammary tumors.
Lee CH; Kweon OK
J Vet Sci; 2002 Dec; 3(4):321-5. PubMed ID: 12819382
[TBL] [Abstract][Full Text] [Related]
12. The expression of p63 and cytokeratin 5 in mixed tumors of the canine mammary gland provides new insights into the histogenesis of these neoplasms.
Ramalho LN; Ribeiro-Silva A; Cassali GD; Zucoloto S
Vet Pathol; 2006 Jul; 43(4):424-9. PubMed ID: 16846983
[TBL] [Abstract][Full Text] [Related]
13. The investigation of transcriptional repression mediated by ZEB2 in canine invasive micropapillary carcinoma in mammary gland.
Gamba CO; Damasceno KA; Ferreira IC; Rodrigues MA; Gomes DA; Alves MR; Rocha RM; Lima AE; Ferreira E; Cassali GD
PLoS One; 2019; 14(1):e0209497. PubMed ID: 30645591
[TBL] [Abstract][Full Text] [Related]
14. COX-2, mPGES-1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours.
Millanta F; Asproni P; Canale A; Citi S; Poli A
Vet Comp Oncol; 2016 Sep; 14(3):270-80. PubMed ID: 24824420
[TBL] [Abstract][Full Text] [Related]
15. c-erbB-2 expression and nuclear pleomorphism in canine mammary tumors.
Dutra AP; Granja NV; Schmitt FC; Cassali GD
Braz J Med Biol Res; 2004 Nov; 37(11):1673-81. PubMed ID: 15517084
[TBL] [Abstract][Full Text] [Related]
16. The combined expression pattern of BMP2, LTBP4, and DERL1 discriminates malignant from benign canine mammary tumors.
Klopfleisch R; Klose P; Gruber AD
Vet Pathol; 2010 May; 47(3):446-54. PubMed ID: 20375427
[TBL] [Abstract][Full Text] [Related]
17. Molecular cloning and tumour suppressor function analysis of canine REIC/Dkk-3 in mammary gland tumours.
Ochiai K; Watanabe M; Azakami D; Michishita M; Yoshikawa Y; Udagawa C; Metheenukul P; Chahomchuen T; Aoki H; Kumon H; Morimatsu M; Omi T
Vet J; 2013 Sep; 197(3):769-75. PubMed ID: 23732075
[TBL] [Abstract][Full Text] [Related]
18. Establishment of primary mixed cell cultures from spontaneous canine mammary tumors: Characterization of classic and new cancer-associated molecules.
Gentile LB; Nagamine MK; Biondi LR; Sanches DS; Toyota F; Giovani TM; de Jesus IP; da Fonseca IIM; Queiroz-Hazarbassanov N; Diaz BL; Salles Gomes COM; Dagli MLZ
PLoS One; 2017; 12(9):e0184228. PubMed ID: 28945747
[TBL] [Abstract][Full Text] [Related]
19. Five markers useful for the distinction of canine mammary malignancy.
Pawłowski KM; Maciejewski H; Majchrzak K; Dolka I; Mol JA; Motyl T; Król M
BMC Vet Res; 2013 Jul; 9():138. PubMed ID: 23844591
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA expression patterns in canine mammary cancer show significant differences between metastatic and non-metastatic tumours.
Bulkowska M; Rybicka A; Senses KM; Ulewicz K; Witt K; Szymanska J; Taciak B; Klopfleisch R; Hellmén E; Dolka I; Gure AO; Mucha J; Mikow M; Gizinski S; Krol M
BMC Cancer; 2017 Nov; 17(1):728. PubMed ID: 29115935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
